Therapy of Alzheimer's Disease with an antibody against oligomeric pyro-Glu-Abeta peptides Scientists at the University of Göttingen developed a novel, proprietary antibody for the therapy and/or diagnosis of Alzheimer's Disease (AD) through the targeting of specifically pyro-Glu-Amyloid beta peptides.
1-vector otoferlin DFNB9 gene therapy Due to the large OTOF size a one-vector delivery has remained challenging.Our technology: Gene-therapy of the otoferlin gene (OTOF) with overloaded AAV virus mediated delivery into the cochlea. In vivo proof-of-concept successfully achieved.
Prevention of Fibrosis and Organ Protection Prevention of Fibrosis and Organ Protection by preconditioning cells via ARNT regulation, i.e. via low-dose tacrolimus, GPI-1046, LB100 or via gene-therapy.
Targeted Demethylating Gene Therapy of Fibrosis All-in-one construct dCas9-TET3CD-(target gene)-sgRNA for targeted fibrosis therapy through demethylation of the genes RASAL1, LRFN2, KLOTHO (i.e. in heart, kidney, liver, lung, cancer). Normal re-expression of these genes has been achieved successfully in vitro and in vivo as well as a reduction of fibrosis.
Pharmacologically controlled vector for CNS gene therapies Gene therapies are irreversible and not controlable in case of side effects. We offer a pharmacologically controlled one-vector expression system of a therapeutic factor (i.e. GDNF) with zero background expression, based on mifepristone (Mfp)-Gene Switch system, for the therapy of neurological diseases.
Restoration of DFNB83 deafness Our technology restores hearing with a virus-mediated delivery of CaBP2 for a gene-therapy of DFNB83. A one-vector system for CaBP2 (Ca+2 binding protein 2) is delivered directly into the cochlea. In a CaBP2 knock-out mouse model we showed transduction of inner hair cells and restoration of hearing.
Treatment of cardiac arrhythmia via re-expression of TBX5 (gene therapy) Cardiovascular disease is the number one cause of death worldwide. Scientists at the University Medical Center Göttingen developed a gene therapy (TBX5 re-expression) for use in the prevention or therapeutic treatment of a ventricular heart disease and associated complications (e.g. cardiac arrhythmia and sudden cardiac death).
Iron-paraCEST-MRI-Contrast-Agents We developed first row transition metal ions (i.e. Fe/ iron) supported by macrocyclic ligands to provide alternatives to lanthanide contrast agents for MRI- thus NOT using gadolinium. The tripodal Schiff base ligands provide water-soluble coordination complexes with i.e. iron, providing signal contrast in MRI.
Leucodistrophy-Repositioning: Laquinimod for Zellweger-Syndrome Zellweger Syndrome spectrum, an orphan disease, is a peroxisomal biogenesis disorder with no treatment currently available. We offer the use of the clinically known Laquinimod (developed for multiple sclerosis) for the therapy of Zellweger Syndrom, for which we achieved successfully an in vivo proof-of-concept.
Bio-engineered neuronal organoids from human stem cells Scientists at the University Medical Center Göttingen, Germany developed a reproducible, robust and fully defined method for serum-free production of human bio-engineered neuronal organoids (BENOs) from stem cells. This new method will allow for reproducible production of oganoids with fully functional neuronal network activity.
New therapy for amyotrophic lateral sclerosis Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease is one of the most common degenerative neuromuscular diseases worldwide and characterized by rapidly progressive weakness and muscle atrophy throughout the body. Scientists at the University of Göttingen developed a new neuroprotective therapeutic approach for ALS.
Drug Delivery Vehicle/Plattform into brain Scientists of the University of Göttingen developed a novel vehicle for the targeted delivery of drugs into the brain parenchyma, particularly useful for the delivery of biologics, like e.g. proteins or antibodies.
GMP-compatible Methods for producing tissue-engineered human heart muscle from stem cells Heart tissue engineering using stem cells is a recently developed technique to construct a three dimensional cell structure from cardiomyocytes or directly from progenitor cells. Scientists at the University of Göttingen developed two new and fully defined methods for serum-free production of engineered human heart muscles.
Prevention and Treatment of Mastitis with Probiotics Mastitis continues to be the most important economic risk for dairy farmers. Current treatment rely heavily on antibiotics, which is costly and frequently ineffective due to increased spread of antibiotic resistance. Scientists at the University of Applied Sciences and Arts Hannover developed a probiotic and protective teat dip.
Humanized anti-CCR2 Antibody for the Therapy of MS and RA Scientists of the University of Göttingen and of the University of Regensburg developed in collaboration a proprietary anti-CCR2 antibodies for the therapy of Multiple Sclerosis (MS) and potentially Rheumatoid Arthritis (RA).The lead candidate Doc-2 has been humanized in collaboration with the MRC Technologies. It targets the CCR2 receptor and modulates the autoimmune process through depletion of CCR2+ monocytes.
New bifunctional Prodrugs with cleavable linker for targeted tumor therapy (ADC) Scientists at the University of Göttingen in Germany developed new and highly potent drugs with cleavable chemical linkers to develop tumor specific antibodies for selective tumor therapy (ADC). The soluble prodrugs are activated into highly cytotoxic drugs only in targeted tumor cells.
Prodrugs/drugs for a selective ADEPT/ADC tumor therapy Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs. Selectivity is achieved by antibody tumor targeting. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site.
Method for increasing the safety of tissue engineered products for clinical use Regenerative medicine is the replacement of diseased tissues with tissue engineered products (TEPs). Stem cells have emerged as the most important source for TEPs. However they carry the risk of uncontrolled cell growth. To solve this problem the present invention uses radiation for mitotic inactivation without loss of function.
